The abstract is read at the publisher; the summary is JClub's.
The ITCC-P4 platform established 353 patient-derived xenograft models from diagnostic and relapsed pediatric cancers, enabling mechanism-informed in vivo drug testing across major high-risk solid types.
- Why it matters: Pediatric cancer survival is limited by tumor heterogeneity and few mechanism-of-action–based therapeutic options, creating a need for predictive, patient-relevant preclinical models.
- What they did: The EU-IMI2 ITCC-P4 partnership built and molecularly characterized 353 PDX models with matched germline/tumor samples, including serial diagnostic/posttreatment, primary/relapse, and metastasis-derived pairs.
- The result: Proof-of-concept screening in neuroblastoma and rhabdomyosarcoma identified potential predictive biomarkers for targeted therapy, and the molecular dataset at https://r2platform.com/itcc-p4 supports selecting models for preclinical testing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.